X0306 4 2021-05-04 0 0001785530 Werewolf Therapeutics, Inc. HOWL 0001609492 MPM BioVentures 2014, L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001609493 MPM BioVentures 2014 (B), L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001765021 MPM BioVentures 2014 LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001765091 MPM BioVentures 2014 GP LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001473930 Foley Todd C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001609495 MPM Asset Management Investors BV2014 LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 Common Stock 2021-05-04 4 C 0 2298430 A 2298430 I See Footnote Common Stock 2021-05-04 4 C 0 763809 A 3062239 I See Footnote Common Stock 2021-05-04 4 P 0 125759 16.00 A 3187998 I See Footnote Series A Preferred Stock 2021-05-04 4 C 0 19925321 0.00 D Common Stock 2298430 0 I See Footnote Series B Preferred Stock 2021-05-04 4 C 0 6621546 0.00 D Common Stock 763809 0 I See Footnote Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. The shares are held as follows: 2,087,358 by MPM BioVentures 2014, L.P. ("BV 2014"), 139,224 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 71,848 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a Managing Director of BV LLC. Each Reporting Persons disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. The shares are held as follows: 2,781,025 by BV 2014, 185,490 by BV 2014(B) and 95,724 by AM BV2014. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. The shares were purchased as follows: 114,210 by BV 2014, 7,618 by BV 2014(B) and 3,931 by AM BV2014. The shares are held as follows: 2,895,235 by BV 2014, 193,108 by BV 2014(B) and 99,655 by AM BV2014. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. The shares were held as follows: 2,087,358 by BV 2014, 139,224 by BV 2014(B) and 71,848 by AM BV2014. No securities held by the Reporting Persons. The shares were held as follows: 693,667 by BV 2014, 46,266 by BV 2014(B) and 23,876 by AM BV2014. /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P. 2021-05-06 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P. 2021-05-06 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC 2021-05-06 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC 2021-05-06 /s/ Todd Foley 2021-05-06 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC 2021-05-06